Modern therapeutic approaches for β-thalassemia: from blood transfusion to gene therapy
Open Access
- 14 January 2026
- journal article
- Published by OOO Grafika in Russian Journal of Pediatric Hematology and Oncology
- Vol. 12 (4) , 56-67
Abstract
Beta-thalassemia is a hereditary disorder caused by pathogenic variants in the HBB gene that lead to impaired synthesis of β-globin chains, resulting in ineffective erythropoiesis, development of microcytic hypochromic anemia, and a complex of systemic complications. This article reviews current therapeutic strategies for this condition. Adequate transfusion support combined with regular chelation therapy remains the cornerstone of standard treatment. In current practice, other methods of conservative therapy are also used, such as those targeting fetal hemoglobin induction, stimulation of erythropoiesis, and other pathogenetic mechanisms. Allogeneic hematopoietic stem cell transplantation was until recently the only method capable of providing a complete cure for β-thalassemia. However, its application is limited by the availability of a fully compatible donor and the risks of transplantation complications, including a high risk of graft failure in this disease and graft-versushost disease. The development of gene therapy aimed at restoring β-globin synthesis or inducing fetal hemoglobin expression offers prospects for functional cure without the need for allogeneic hematopoietic stem cell transplantation, overcoming many of its limitations, including the lack of an optimal donor, graft-versus-host disease, and graft rejection. This review provides an analysis of existing treatment methods, their limitations, and the potential for clinical application of gene therapy in β-thalassemia.Keywords
This publication has 63 references indexed in Scilit:
- New Gene Therapy for β-ThalassemiaJAMA, 2022
- CRISPR/Cas9-based multiplex genome editing of BCL11A and HBG efficiently induces fetal hemoglobin expressionEuropean Journal of Pharmacology, 2022
- Busulfan–fludarabine- or treosulfan–fludarabine-based myeloablative conditioning for children with thalassemia majorAnnals of Hematology, 2022
- Current status of beta‐thalassemia and its treatment strategiesMolecular Genetics & Genomic Medicine, 2021
- Luspatercept: First ApprovalDrugs, 2020
- Allogeneic Hematopoietic Stem Cell Transplantation to Cure Transfusion-Dependent Thalassemia: Timing Matters!Transplantation and Cellular Therapy, 2018
- Direct Promoter Repression by BCL11A Controls the Fetal to Adult Hemoglobin SwitchCell, 2018
- A Potential Therapy for Beta-Thalassemia (ST-400) and Sickle Cell Disease (BIVV003)Transplantation and Cellular Therapy, 2018
- A New Stratification Strategy That Identifies a Subset of Class III Patients with an Adverse Prognosis among Children with β Thalassemia Major Undergoing a Matched Related Allogeneic Stem Cell TransplantationTransplantation and Cellular Therapy, 2007
- Hemoglobin Switching in Humans Is Accompanied by Changes in the Ratio of the Transcription Factors, GATA-1 and SP1Molecular Medicine, 1995